Tarsus Pharmaceuticals (TARS)
Commercializes XDEMVY for Demodex blepharitis and develops additional eye-care and infectious-disease therapies.
$76.07
vs last close−1.02 (−1.32%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 107.13% | 47.01M shares | |
|---|---|---|---|
| 270 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 3.02% | 1.33M shares | |
| 14 holders · as of Sep 17, 2026 | |||
| Strategic holders | 5.11% | 2.24M shares | |
| 1 holder · as of May 15, 2026 | |||
| Adds to | 115.26% | ||
43.88M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 115.26%; nothing is left for Other.
13F, as of Jun 30, 2026
270 holders · 47.01M shares · 43 new positions · 146 increased · 87 reduced · 35 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 3.86M | 8.79% | +303.5K | Aug 7, 2026 |
| Deep Track Capital, LP | 3.67M | 8.36% | +66.8K | Aug 14, 2026 |
| RTW Investments, LP | 3.36M | 7.65% | +11.0K | Aug 14, 2026 |
| Jupiter Topco LLC | 2.81M | 6.40% | +2.81Mnew | Aug 14, 2026 |
| Paradigm Biocapital Advisors LP | 2.78M | 6.33% | +213.5K | Aug 14, 2026 |
| Morgan Stanley | 1.83M | 4.16% | −117.2K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 1.79M | 4.09% | +32.5K | Aug 13, 2026 |
| Jennison Associates LLC | 1.66M | 3.79% | −48.5K | Aug 3, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Deep Track Capital, LP | 8.46% | 3.60M | 13G | May 15, 2026 |
| RTW Investments, LP | 8.10% | 3.42M | 13G | Aug 14, 2025 |
| BlackRock, Inc. | 7.40% | 3.09M | 13G | Apr 24, 2025 |
| Janus Henderson Group PLC | 5.30% | 2.24M | 13G | May 15, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 15, 2026 | William J. Phd Linkdirector | Sale · 3 lots | 12,500 | $78.38 | 94,487 |
| Sep 4, 2026 | Seshadri Neervannanofficer: Chief Operating Officer | Sale | 4,564 | $85.00 | 78,532 |
| Sep 4, 2026 | Elizabeth Yeu Linofficer: Chief Medical Officer | Sale · 4 lots | 13,953 | $87.50 | 4,137 |
| Sep 4, 2026 | Bobak R. Azamiandirector, officer: President/CEO and Board Chair | Sale · 2 lots | 10,000 | $90.56 | 827,991 |
| Sep 2, 2026 | Elizabeth Yeu Linofficer: Chief Medical Officer | Sale · 2 lots | 6,977 | $80.00 | 18,090 |
| Sep 1, 2026 | Elizabeth Yeu Linofficer: Chief Medical Officer | Sale | 4,601 | $73.86 | 18,707 |
| Sep 2, 2026 | Bobak R. Azamiandirector, officer: President/CEO and Board Chair | Sale | 10,000 | $80.06 | 837,991 |
| Jun 17, 2026 | Bobak R. Azamiandirector, officer: President/CEO and Board Chair | Sale · 2 lots | 10,000 | $61.55 | 847,991 |
| Jun 15, 2026 | William J. Phd Linkdirector | Sale · 2 lots | 12,500 | $62.12 | 106,786 |
| Jun 15, 2026 | Katherine Goodrichdirector | Sale | 2,954 | $62.08 | 2,233 |
House and Senate disclosures
Not reported.